Lonza Group AG (LONN.SW)
Lonza Group AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Basel, BS, CH. The stock last traded at $570.20, up 0.71% on the session, giving a market capitalisation of $39.83B. Its beta of 0.84 implies it has historically moved less than the broad market.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Lonza Group AG is most often compared with the following Healthcare names: